Best overall response
| ADX+NIVO n=72 | NIVO only n=72 | |
| Best overall response | ||
| CR, n (%) | 1 (1.4) | 0 |
| PR, n (%) | 6 (8.3) | 5 (6.9) |
| SD, n (%) | 15 (20.8) | 12 (16.7) |
| PD, n (%) | 47 (65.3) | 47 (65.3) |
| Discontinued before first assessment, n (%) | 3 (4.2) | 8 (11.1) |
| Objective response rate | ||
| Responders (CR+PR) | 7 (9.7%) | 5 (6.9%) |
| 95% CI | 4.0 to 19.0 | 2.3 to 15.5 |
| OR for objective response rate | 1.5 | |
| 95% CI | 0.4 to 6.1 | |
| P value for CMH test* | 0.8 | |
*P value versus NIVO Only from CMH test for disease control rate, and from log-rank test for duration of response.
ADX, andecaliximab; CMH, Cochran-Mantel-Haenszel; CR, complete response; NIVO, nivolumab; PD, progressive disease; PR, partial response; SD, stable disease.